Navigation Links
Statin Therapy Cuts Bad Cholesterol Unprecedented 70 Percent

Research conducted at the Methodist DeBakey Heart Center in Houston shows that a combination statin therapy lowers bad cholesterol by an unprecedented// 70 percent, and has the added benefit of reducing life-threatening inflammation that can lead to heart disease and stroke.

The results published this week in the American Journal of Cardiology, also show 46 percent reduction in C-reactive protein (CRP), a marker for inflammation, in patients treated with 40 mg of rosuvastatin and 10 mg ezetimibe.

“A seventy percent drop is the largest reduction in bad cholesterol ever seen in a statin clinical trial. Cardiologists have long recognized the challenge in helping high-risk patients reach their target cholesterol levels, to ultimately prevent heart attack and stroke,” said Dr. Christie Ballantyne, cardiologist at the Methodist DeBakey Heart Center and principal investigator for the study. “These results offer hope for these patients.”

In addition, inflammation can lead to serious complications such as heart attack and stroke, and high levels of CRP can predict these risks years before they actually occur, Ballantyne said. Physicians have long relied on blood cholesterol as a key indicator of cardiovascular risk, but recent research suggests that high risk patients who achieved a low CRP level combined with a low LDL-c level had the fewest cardiovascular events.

“The highly effective reductions in both LDL-c and CRP seen in the EXPLORER study provide a new opportunity for high-risk patients to achieve optimal reduction in both factors with combination therapy,” Ballantyne said.

Key findings from EXPLORER** study:

* Crestor and Zetia reduced mean LDL-C by an unprecedented 70%.

* Significantly (p<0.001) more patients achieved their NCEP ATP III LDL-C goal of <100 mg/dL (94% vs. 79%) at six weeks with Crestor and Zetia compared with Crestor monotherapy.

* Crestor and Zetia reduc ed CRP levels by 46% compared with 29% with Crestor monotherapy.

* Both CRESTOR monotherapy and CRESTOR combined with ezetimibe produced similar increases in HDL-C (“good” cholesterol) (8.5% vs. 10.8%).

* CRESTOR and ezetimibe were both well tolerated.

** EXPLORER (Examination of Potential Lipid modifying effects Of Rosuvastatin in combination with Ezetimibe versus Rosuvastatin alone) was a 12-week, randomized trial of 469 patients with LDL-C 160-<250 mg/dL (4.1-<6.5 mmol/L) and coronary heart disease (CHD) or CHD risk equivalent designed to evaluate whether adding ezetimibe to CRESTOR would enable more patients with severely high cholesterol to achieve guideline lipid goals compared with CRESTOR monotherapy. Patients participated in a six-week dietary lead-in followed by six weeks of randomized treatment with rosuvastatin 40 mg alone or in combination with ezetimibe 10 mg.

Source-NewswiseBR>SRM
'"/>




Related medicine news :

1. Statins reduce heart attacks
2. Statins reduce risks for angioplasty patients
3. Statins Found To Be Helpful For Patients With Arthritis
4. Long-Term Benefits Of Statins Questioned
5. Higher Statin Dose Safely Reduces Stroke and Cardiac Arrest
6. Use of Statin can help in recovery from stroke
7. Statins Not Effective In Treating Calcific Aortic Stenosis
8. Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients
9. The Effects of Statins Questioned
10. Statins Taken For Reducing Cholesterol Found To Reduce Death Rate Associated With Heart Attack As Well
11. Study Finds No Link Between Statins And Breast Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... TX (PRWEB) , ... March 23, 2017 , ... March ... organs that pack a punch when it comes to maintaining good health. Every day, ... 30 minutes, your kidneys filter every drop of your blood, eliminating waste, regulating fluid ...
(Date:3/23/2017)... Angeles, CA (PRWEB) , ... March 23, 2017 ... ... A funding investment in Los Angeles based healthcare technology company California Healthcom Group ... portfolio into the US, and healthcare arena. With headquarters in California, CHG is ...
(Date:3/23/2017)... ... March 23, 2017 , ... Michael ... of the greater Fort Collins area, has unveiled a collaboration with nonprofit Big ... program. Donations to this worthy cause may now be made at http://bigbonescaninerescue.com/ ...
(Date:3/23/2017)... ... March 23, 2017 , ... Altec ... The Resource Group as their 2016 Microsoft Dynamics Partner of the Year at ... CA. The award recognizes The Resource Group for their outstanding relationship with ...
(Date:3/23/2017)... OR (PRWEB) , ... March 23, 2017 , ... Sharon ... Water, Global Climate Change and Your Health on VoiceAmerica, recently talked on her program ... she also used the occasion to remind listeners of an important distinction. World Water ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... CRANBURY, N.J. , March 23, 2017 ... pharmaceutical company, announced a major milestone today.  ... meetings with the U.S. Food and Drug ... a clear clinical and regulatory path forward ... compound, CPI-613, in patients with acute myeloid ...
(Date:3/23/2017)... 2017 On Wednesday, March ... session at 5,821.64, up 0.48%; the Dow Jones ... 20,661.30; and the S&P 500 closed at 2,348.45, ... six out of nine sectors ended the day ... coverage on the following Medical Instruments & Supplies ...
(Date:3/23/2017)... 2017 Piramal Pharma ... gibt die Ernennung von Stuart E. Needleman ... globalen Pharmazeutikkunden eine einmalige integrierte End-to-End-Serviceplattform an ... für das erfolgreiche Wachstum und die Umsetzung ... Herr Needleman dafür verantwortlich sein, alle globalen ...
Breaking Medicine Technology: